Lees ook het artikel: broccoli verrijkt met selenium remt darmkankergroei
24 februari 2014: Bron: J Nephropathol. 2013 April; 2(2): 129–134.Published online 2013 April 1. doi: 10.12860/JNP.2013.21
Selenium kan nierschade voorkomen bij mensen die per infuus cisplatin krijgen. Dit blijkt uit een gerandomiseerde dubbelblinde studie bij totaal 122 patiënten met verschillende vormen van kanker die als behandeling in ieder geval cisplatin per infuus kregen toegediend.
Nierschade (nefrotoxiciteit - AFR) komt vaak voor bij cisplatin. Er zijn wel enkele middelen die worden gebruikt om nierschade te verminderen. maar geen van die middelen heeft bewezen effectief te zijn. Behalve dan hydration - water met een zoutoplossing toevoegen, wat nog wel eens wil helpen, maar vaak onvoldoende. Nu hebben onderzoekers onderzocht in een dubbelblinde gerandomiseerde studie wat het effect is van toevoeging van 400 mg selenium in tabletvorm aan de hydratie naast de cisplatin.
Resultaten:
122 patiënten ( 85 mannen en 37 vrouwen, in leeftijd van 14 - 82 jaar oud ) met verschillende vormen van kanker namen deel aan deze studie. alle patiënten kregen chemotherapie met in ieder geval cisplatin erbij. De ene helft van de groep (willekeurig ingedeeld) kreeg daarnaast een tabletje met selenium (400mg) en de andere helft een placebo tabletje. Er was geen verschil in de toegediende dosis cisplatin tussen de groepen ( p = 00:54 ).
In de placebgroep deden zich 7 gevallen van nierschade (ARF) voor terwijl in de seleniumgroep er zich geen enkel geval van nierschade voordeed.
Conclusie:
De conclusie van de onderzoekers blijkt dan ook dat toegevoegde selenium door cisplatin geïnduceerde acute nierschade kan voorkomen bij kankerpatiënten.
Het volledige studierapport: Protective effect of selenium on cisplatin induced nephrotoxicity: A double-blind controlled randomized clinical trial is gratis in te zien.
Hier het abstract van deze studie met daaronder een referentielijst gerelateerd aan dit onderwerp:
Selenium could probably prevent cisplatin-induced acute kidney injury, when it is added to hydration therapy in cancerous patients
J Nephropathol. 2013 April; 2(2): 129–134.
Protective effect of selenium on cisplatin induced nephrotoxicity: A double-blind controlled randomized clinical trial
Abstract
Background: Renal injury is common following cisplatin infusion. Some agents have been used to attenuate cisplatin nephrotoxicity. However, except hydration, none of them has been proved to be effective.
Objective:In this study selenium as an antioxidant supplement was tested on cisplatin induced renal injury.
Patients and Methods: 122 cancerous patients (85 male and 37 female; age range of 14 to 82 years old) were enrolled to receive chemotherapy regimens consisting cisplatin. They were allocated into two groups using a random number list . Investigators, patients and analyzers all, were blinded in allocation by using sealed opaque envelopes. Intervention group received a single 400 mcg selenium tablet and patients in control group took a placebo tablet which was similar with selenium preparation in color, weight, shape and taste. Primary end points were an increase in plasma creatinine above 1.5 mg/dl in men and 1.4mg/dl in women, or increase of plasma creatinine more than 50% from baseline or urine flow rate less than 0.5 ml/kg/h. Creatinine level was measured initially and on the 5th day after cisplatin therapy.
Results: There was no difference in cumulative dose of cisplatin between the groups (p=0.54). There were not evidences of acute renal failure (ARF) in cases. While, among placebo group, 7 patients had criteria of acute kidney injury.
Conclusions :selenium could probably prevent cisplatin-induced acute kidney injury, when it is added to hydration therapy in cancerous patients.
References
1. Rose B, Post T. Rose clinical physiology of acid-base and electrolyte disorder. 5th edition. New York: McGraw-Hill 2001; 251-9.
2.
Kim SW, Lee JU, Nah MY, Kang DG, Ahn KY, Lee HS. et al. Cisplatin decreases the abundance of aquaporin water channels in rat kidney. J Am Soc Nephrol. 2001;12(5):875–82. [PubMed]
3.
Ciarimboli G, Ludwig T, Lang D, Pavenstädt H, Koepsell H, Piechota HJ. et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol.2005;167(6):1477–84. [PMC free article] [PubMed]
4.
Portilla D, Li S, Nagothu KK, Megyesi J, Kaissling B, Schnackenberg L. et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int. 2006;69(12):2194–204. [PubMed]
5.
Wittes RE, Brescia F, Young CW, Magill GB, Golbey RB, Krakoff IH. Combination chemothereapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of the head and neck. Oncology.1975;32(5-6):202–7. [PubMed]
6.
Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer.1977;39(4):1357–61. [PubMed]
7.
Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin Oncol. 1999;26(2):72–81. [PubMed]
8.
Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis. 1986;8(5):368–79. [PubMed]
9.
Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL. et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97(6):845–51. [PubMed]
10.
Wu YJ, Muldoon LL, Neuwelt EA. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther. 2005;312(2):424–31.[PubMed]
11.
Benoehr P, Krueth P, Bokemeyer C, Grenz A, Osswald H, Hartmann JT. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. J Am Soc Nephrol. 2005;16(2):452–8. [PubMed]
12.
Heyman SN, Spokes K, Egorin MJ, Epstein FH. Glycine reduces early renal parenchymal uptake of cisplatin. Kidney Int. 1993;43(6):1226–8. [PubMed]
13.
Stark JJ, Howel SB. Nephrotoxicity of cis-platinum (II) dichlorodiammine. Clin Pharmacol Ther.1978;23(4):461–6. [PubMed]
14.
Hu YJ, Chen Y, Zhang YQ, Zhou MZ, Song XM, Zhang BZ. et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res.1997;56(3):331–41. [PubMed]
15.
Fujieda M, Naruse K, Hamauzu T, Miyazaki E, Hayashi Y, Enomoto R. et al. Effect of selenium on Cisplatin-induced nephrotoxicity in rats. Nephron Exp Nephrol. 2006;104(3):e112–22. [PubMed]
16.
Weijl NI, Elsendoorn TJ, Lentjes EG, Hopman GD, Wipkink-Bakker A, Zwinderman AH. et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer. 2004;40(11):1713–23. [PubMed]
17.
Francescato HD, Costa RS, Rodrigues Camargo SM, Zanetti MA, Lavrador MA, Bianchi MD. Effect of oral selenium administration on cisplatin-induced nephrotoxicity in rats. Pharmacol Res.2001;43(1):77–82. [PubMed]
18.
Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology. 2004;195(2-3):221–30. [PubMed]
19.
Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20(12):2895–903. [PubMed]
20.
Winston JA, Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol. 1985;249(4 Pt 2):F490–6. [PubMed]
Articles from Journal of Nephropathology are provided here courtesy of Society of Diabetic Nephropathy
voedingsuppletie, literatuurlijst Valstar, voeding, antioxydanten, nefrotoxiciteit - AFR, nierfalen, nierschade, selenium
Gerelateerde artikelen
Plaats een reactie ...
Reageer op "Selenium kan nierschade voorkomen bij mensen die per infuus cisplatin krijgen."